Purpose The goal of the study was to assess the prognostic and predictive values of 18F-FDG PET/CT and CT in patients with breast invasive ductal cancer, already treated with surgery and/or chemotherapy and/or radiotherapy Methods and Materials We enrolled 157 females (mean age 62±11 years) with a previous history of breast invasive ductal cancer after primary treatment. They underwent within three months both CT and 18F-FDG PET/CT examinations for the evaluation of disease status. The median interval time between the last treatment (surgery and chemotherapy and/or radiotherapy) and imaging exams was 55±5 months. Follow-up data were obtained with clinical evaluation and/or radiological findings. Results The follow-up was 100% complete in a period of 13±9 months. Of the overall patients, 51 (33%) had evidence of clinical and/or radiological relapse of disease, while 106 (67%) did not (Figure 1). The negative predictive value (NPV) and the positive predictive value (PPV) for disease relapse or progression were of 83% vs. 77% and 44% vs. 38%, respectively for PET/CT and CT. The relapse-free survival (Kaplan-Meier method) in patients with negative PET/CT was significant different from patients with positive PET/ CT (78% vs. 20%; log-rank test 12.2, p<0.001). In patients with negative and positive CT, the relapse-free survival were of 53% and 38%, respectively (long rank test 0.27, p=NS) (Figure 2 and 3, respectively).Conclusion PET/CT imaging could be considered a valid tool for the prognostic evaluation in patients with breast cancer after primary treatment during a long-period follow-up. For the identification of disease relapse, FDG PET/CT has demonstrated, high NPV but low PPV, although superior to CT.
Comparison between 18F-FDG PET/CT and ComputedTomography for Prognostic Evaluation in Patients withBreast Invasive Ductal Cancer
POMERRI, FABIO;MUZZIO, PIER CARLO
2011
Abstract
Purpose The goal of the study was to assess the prognostic and predictive values of 18F-FDG PET/CT and CT in patients with breast invasive ductal cancer, already treated with surgery and/or chemotherapy and/or radiotherapy Methods and Materials We enrolled 157 females (mean age 62±11 years) with a previous history of breast invasive ductal cancer after primary treatment. They underwent within three months both CT and 18F-FDG PET/CT examinations for the evaluation of disease status. The median interval time between the last treatment (surgery and chemotherapy and/or radiotherapy) and imaging exams was 55±5 months. Follow-up data were obtained with clinical evaluation and/or radiological findings. Results The follow-up was 100% complete in a period of 13±9 months. Of the overall patients, 51 (33%) had evidence of clinical and/or radiological relapse of disease, while 106 (67%) did not (Figure 1). The negative predictive value (NPV) and the positive predictive value (PPV) for disease relapse or progression were of 83% vs. 77% and 44% vs. 38%, respectively for PET/CT and CT. The relapse-free survival (Kaplan-Meier method) in patients with negative PET/CT was significant different from patients with positive PET/ CT (78% vs. 20%; log-rank test 12.2, p<0.001). In patients with negative and positive CT, the relapse-free survival were of 53% and 38%, respectively (long rank test 0.27, p=NS) (Figure 2 and 3, respectively).Conclusion PET/CT imaging could be considered a valid tool for the prognostic evaluation in patients with breast cancer after primary treatment during a long-period follow-up. For the identification of disease relapse, FDG PET/CT has demonstrated, high NPV but low PPV, although superior to CT.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
